

NeoCure Therapeutics Announces Positive Top-Line Phase 3 Results for NC-101 in Rare Muscle Degeneration

SAN FRANCISCO, CA – Feb 6, 2026 – NeoCure Therapeutics today announced that its pivotal Phase 3 study of NC-101 met its primary endpoint, demonstrating a statistically significant 45% reduction in muscle fatigue compared to placebo. The trial, involving 250 patients, showed that NC-101 was well-tolerated with a safety profile comparable to the control group.

"These results confirm NC-101 as a breakthrough therapy for patients with limited options," said Dr. Jane Smith, CEO. "We observed no serious treatment-related adverse events and look forward to our FDA filing in Q3."

Key Data:

- **Clinical Phase:** Phase 3
- **Efficacy:** 45% reduction in fatigue ($p < 0.01$)
- **Safety:** Zero (0) serious adverse events (SAEs) reported
- **Status:** Preparing for Q3 NDA submission.